Clinical Trial Update: Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a Shigella sonnei vaccine administered by intradermal, intranasal, or intramuscular routes in healthy adults has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella Sonnei vaccine

Snippet

Sponsor: GSK Vaccines Institute For Global Health S.r.l. | Conditions: Shigellosis | Phase 1 | Status: COMPLETED